Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


March 14, 2005 14 March, 2005

*Pheromone Sciences Corp Announces USA Launch of Fertility Monitor


Toronto, Ontario - March 14, 2005: Pheromone Sciences Corp. (TSX-V:PHS) today announced that HealthWatchSystems Inc. has launched the OV Watch(tm) product in selected markets in the USA. The OV Watch(tm) fertility monitor is a watch like fertility cycle monitoring device, designed and developed by Pheromone Sciences, for the consumer and professional medical market. The OV Watch(tm) looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning through the measurement of perspiration ion changes on the surface of the skin. These changes in female perspiration allow for the prediction of ovulation up to 4 days prior to the day of ovulation without the need for inconvenient urine or blood testing. This advance notice can significantly improve a women's probability of success in conceiving a child.

The OV-Watch(tm) will be competing in a marketplace that is estimated to be valued at US $500 million in America alone. Pheromone Sciences Corporation will receive a stream of royalties based upon the worldwide sales generated by HealthWatchSystems Inc.

More information can be found on both the OV Watch(tm) and HealthWatchSystems Inc. at the website www.ovwatch.com

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company currently seeking new product and technology development opportunities.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.